Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.
Canta
F
F
Marrone
R
R
Bonora
S
S
D'Avolio
A
A
Sciandra
M
M
Sinicco
A
A
De Rosa
F G
FG
Di Perri
G
G
D000328:Adult; D000368:Aged; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D016174:Hepacivirus / Q000187:drug effects* / Q000378:metabolism; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000493:pharmacokinetics / Q000633:toxicity*; D019438:Ritonavir / Q000493:pharmacokinetics / Q000633:toxicity*
D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir